SCHEMBL6155587

SCHEMBL6155587

CC(CCCC(C)(C)O)c1cccc(OCc2ccc(C(O)O)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYSLTR2 Q9NS75 1/20 0.44
CYSLTR1 Q9Y271 1/20 0.44
FFAR1 O14842 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
BCHE P06276 1/20 0.40
APP P05067 1/20 0.39
ALOX5 P09917 2/20 0.39
NR4A1 P22736 1/20 0.39
NR4A2 P43354 1/20 0.39
NR4A3 Q92570 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SPHK1 Q9NYA1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6155248 0.97 CYSLTR2 (0.42) CYSLTR2CYSLTR1FFAR1KMT2AMEN1
SCHEMBL2785504 0.89 CYSLTR2 (0.40) CYSLTR2CYSLTR1FFAR1KMT2AMEN1
SCHEMBL2107789 0.88 MRGPRX4 (0.44) CYSLTR2CYSLTR1FFAR1BCHEALOX5
SCHEMBL6155616 0.87 ALOX5 (0.39) CYSLTR2CYSLTR1FFAR1KMT2AMEN1
SCHEMBL6155510 0.86 MAPK1 (0.39) CYSLTR2CYSLTR1FFAR1KMT2AMEN1
SCHEMBL6886826 0.84 RRM1 (0.47) KMT2AMEN1BCHEAPPALOX5
SCHEMBL6155571 0.83 VDR (0.46) CYSLTR2CYSLTR1FFAR1BCHEALOX5
SCHEMBL2107020 0.82 CYP4F2 (0.46) FFAR1KMT2AMEN1BCHEAPP
SCHEMBL2106818 0.82 CYSLTR2 (0.42) CYSLTR2CYSLTR1FFAR1KMT2AMEN1
SCHEMBL2109172 0.81 VDR (0.41) CYSLTR2CYSLTR1FFAR1BCHEAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 EP claimed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 US claimed
US-20050169945-A1 Composition for protecting keratin material, process of making, uses thereof L'OREAL (FR) 2005-08-04 US disclosed
EP-1559398-A1 Process for preparing a composition for the cosmetic treatment of keratinous materials on the basis of a pressurised fluid and vitamins L'OREAL (FR) 2005-08-03 EP disclosed
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 EP disclosed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 US disclosed
EP-1262168-A1 Composition containing fibres to combat the skin aging process L'OREAL (FR) 2002-12-04 EP disclosed
EP-1124779-A1 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2001-08-22 EP disclosed
WO-2000026167-A1 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050169945-A1 Composition for protecting keratin material, process of making, uses thereof KRT18, PROC, CUTA CYSLTR2 3910/4885CYSLTR1 3774/4885FFAR1 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.